ArticleNPJ precision oncology2026
Preoperative positive ctDNA analysis is associated with the tumor microenvironment, and the risk of recurrence in non-metastatic colorectal cancer.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond the biopsy: the new era of non-invasive staging and biomarkers in colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Recurrence after curative-intent surgery for colorectal cancer is a major cause of cancer-related death. Circulating cell-free tumor DNA (ctDNA) is increasingly used in the perioperative setting to detect residual disease. However, the association between preoperative ctDNA, the tumor microenvironment, including tumor-infiltrating lymphocytes, and recurrence is unknown. We explored the association between ctDNA and the tumor microenvironment in patients with non-metastatic CRC undergoing curative-intent surgery. ctDNA was assessed using a tumor-agnostic hypermethylated cfDNA test. Among 140 patients, ctDNA tested positive in 102 (72.9%) before surgery, with 38 (27.1%) tumors classified as immune infiltration high. ctDNA was associated with expression of cancer-metastasis pathways, while immune active phenotypes were associated with immune infiltration high tumors. ctDNA status could identify deficient mismatch repair tumors with an active immune phenotype. The results suggest that a positive ctDNA analysis before surgery is associated with a metastatic tumor microenvironment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.